Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care
Annals of Oncology, ISSN: 0923-7534, Vol: 32, Issue: 10, Page: 1206-1208
2021
- 6Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures6
- Readers6
- Mentions1
- News Mentions1
- News1
Most Recent News
Different Taxanes, Similar Outcomes in Advanced HER2-Positive Breast Cancer
(MedPage Today) -- Final results from a routine-practice comparison of taxane agents showed that the drugs offered comparable safety and efficacy in advanced HER2-positive breast cancer. Median progression-free survival (PFS) was about 21 months...
Article Description
Annals of Oncology
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0923753421039806; http://dx.doi.org/10.1016/j.annonc.2021.08.1750; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85114510661&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/34403778; https://linkinghub.elsevier.com/retrieve/pii/S0923753421039806; https://dx.doi.org/10.1016/j.annonc.2021.08.1750
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know